Clinical trial NCT04515290: A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
Official title: A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Heart Failure
Lead sponsor: Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2020-08-17
Enrollment: 85
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety, efficacy and optimal dose of TSG-01, an innovative drug with ginsenosides as its main components, in the treatment of patients with chronic heart failure(CHF). Preclinical studies have revealed that TSG-01 promote myocardial energy metabolism and ATP production, reduce the damage of human pulmonary microvascular endothelial cell connection, resist arrhythmia, and regulate the lipid metabolism disorder caused by myocardial ischemia. Results from CHF animal models(dog, rat) showed that TSG-01 significantly increase coronary blood supply, improve myocardial contractility, reduce heart expansion and pulmonary edema. Besides its potency of improving heart function, TSG-01 was found to induce diuresis without obvious effect on urine potassium in rats. TSG-01 has been approved by CFDA for a clinical trial on the treatment of CHF (Approval No. 2018L03012). A randomized, double-blind, multicenter, placebo-controlled phase IIa clinical trial is now being conducted in 5 hospitals in China. A total of 90 cases of CHF caused by coronary heart disease are included and randomly divided into three groups: high-dose, low-dose of TSG-01 and placebo group. NYHA functional class, 6-minute walk test(6MHWT) distance, NT-proBNP, left ventricular ejection fraction(LVEF), echocardiographic parameters (LVESV, LVEDV, and heart size) and MLHFQ score are measured before, during and after treatment to evaluate the benefits of TSG-01 therapy in patients with CHF.


Eligibility criteria: Inclusion Criteria:

* Age: 40 to 75 years.
* Have chronic heart failure(CHF) due to ischemic causes and defined as NYHA classification of III.
* Left ventricular ejection fraction (LVEF) of ≤45% and ≥25% as determined by improved biplane Simpson method
* NT-proBNP≥450pg/ml
* Be on a stable regime of standardized therapy for CHF at least 2 weeks prior to receiving study medication and are respected to remain on a stable regime throughout the duration of the trial without the need to receive intravenously vasoactive agents or/and diuretics. Standardized therapy includes ACEI/ARB, beta-blocker, aldosterone receptor antagonist, diuretic, digitalis.
* Is able to understand the trial and provide informed consent.

Exclusion Criteria:

* Has hypertensive cardiopathy, pulmonary heart disease, congenital heart disease, moderate to severe pulmonary hypertension (pulmonary artery pressure ≥ 40mmHg), moderate to severe cardiac valve stenosis or insufficiency, any type of cardiomyopathy(hypertrophic, restrictive or dilated cardiomyopathy); moderate to severe pericardial effusion, constrictive pericarditis, and heart failure caused by arrhythmia.
* Has noncardiogenic heart failure caused by diseases in kidney, lung, liver, or by rheumatic immune disorders, severe infection and chemical factors (chemotherapy, alcohol, etc.).
* Has active tuberculosis or systemic lupus erythematosus (SLE)
* Had acute myocardial infarction, biventricular pacemaker implantation for cardiac resynchronization, cardiothoracic surgery or was complicated with acute coronary syndrome, pulmonary embolism and acute cerebrovascular disease within 3 months prior to receiving study medication.
* Had symptomatic ventricular tachycardia or pleomorphic ventricular tachycardia, cardiogenic shock (CGS), a progressive exacerbation of unstable angina, uncontrolled malignant arrhythmia, second degree sinoatrial or AV block Mobitz Type II or above without pacemaker implantation, QTc\>550 ms and heart rate \<50 bmp. Had uncontrolled hypertension, systolic blood pressure≥180/mmHg and/or diastolic blood pressure≥110mmHg, or hypotension with systolic blood pressure\<90mmHg and/or diastolic blood pressure\<60mmHg.
* Had coronary revascularization procedure (percutaneous or surgical) within 12 weeks prior to receiving study medication or be expected to have coronary revascularization or left ventricular remodeling operation in next 12 weeks.
* Has hepatic abnormality defined as ALT≥1.5 times the upper limit of normal, or has impaired renal function with Cr≥1.5 times the upper limit of normal. Has severe anemia (Hb\<70g/L), pheochromocytoma, hematopathy, gastrointestinal bleeding (consecutive fecal occult blood tests positive, except bleeding caused by hemorrhoids or other anal diseases).
* Has a body weight\>200kg.
* The subject has the need for mechanical ventilation, or has a history of a stroke or any malignancy within 4 weeks prior to receiving study medication.
* Has psychosis with poor control, or is a drug addict who has not been detoxified.
* Allergic to the study drug.
* Has participated in any clinical trial involving experimental therapy 3 months prior to screening.
* If female, being pregnant or lactating, or plan to get pregnant in next 3 months.
* Has a survival time less than 3 months according to the investigator's judgement.
* Subject who are taking Entresto (Sacubitril Valsartan Sodium Tablets) medication.
* Unable to complete the study or comply with the requirements of the study (for management or other reasons) according to the investigator's judgement.

Primary outcomes:
measure: New York Heart Association (NYHA) Classification
timeFrame: 12th week after intervention
measure: Six(6)-minute walk test
timeFrame: 12th week after intervention
Secondary outcomes:
measure: Change of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Level from baseline and placebo
timeFrame: 12th week after intervention
measure: Change in LVEF from screening/baseline as determined by echocardiography
timeFrame: 12th week after intervention
measure: Change in LVESV from screening/baseline as determined by echocardiography
timeFrame: 12th week after intervention
measure: Change in LVEDV from screening/baseline as determined by echocardiography
timeFrame: 12th week after intervention
measure: Change in cardiac size from screening/baseline as determined by echocardiography
timeFrame: 12th week after intervention
measure: Minnesota Living with Heart Failure Questionnaire (MLHFQ)
timeFrame: 12th week after intervention
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan Province Hospital of TCM
state: Henan
city: Zhengzhou
country: China
facility: The first Affiliated Hospital of Henan University of CM
state: Henan
city: Nanjing
country: China
facility: Affiliated Hospital of Nanjing University of Chinese Medicine
state: Jiangsu
city: Shanghai
country: China
facility: Shanghai Shuguang Hospital
state: Shanghai
city: Hangzhou
country: China
facility: Zhejiang Provincial Hospital of Chinese Medicine
state: Zhejiang
Study officials:
References: